JP5329016B2 - 修飾したヒト胸腺ストローマ細胞リンホポエチン - Google Patents

修飾したヒト胸腺ストローマ細胞リンホポエチン Download PDF

Info

Publication number
JP5329016B2
JP5329016B2 JP2003535704A JP2003535704A JP5329016B2 JP 5329016 B2 JP5329016 B2 JP 5329016B2 JP 2003535704 A JP2003535704 A JP 2003535704A JP 2003535704 A JP2003535704 A JP 2003535704A JP 5329016 B2 JP5329016 B2 JP 5329016B2
Authority
JP
Japan
Prior art keywords
polypeptide
tslp
seq
modified
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2003535704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005505293A5 (enExample
JP2005505293A (ja
Inventor
ライマン，スチュアート・ディー
ヴァン・ネス，カーク・ピー
パックストン，レイモンド・ジェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of JP2005505293A publication Critical patent/JP2005505293A/ja
Publication of JP2005505293A5 publication Critical patent/JP2005505293A5/ja
Application granted granted Critical
Publication of JP5329016B2 publication Critical patent/JP5329016B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2003535704A 2001-07-23 2002-07-23 修飾したヒト胸腺ストローマ細胞リンホポエチン Expired - Lifetime JP5329016B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30734501P 2001-07-23 2001-07-23
US60/307,345 2001-07-23
PCT/US2002/023475 WO2003032898A2 (en) 2001-07-23 2002-07-23 Modified human thymic stromal lymphopoietin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010153133A Division JP2010279365A (ja) 2001-07-23 2010-07-05 修飾したヒト胸腺ストローマ細胞リンホポエチン

Publications (3)

Publication Number Publication Date
JP2005505293A JP2005505293A (ja) 2005-02-24
JP2005505293A5 JP2005505293A5 (enExample) 2006-01-05
JP5329016B2 true JP5329016B2 (ja) 2013-10-30

Family

ID=23189325

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003535704A Expired - Lifetime JP5329016B2 (ja) 2001-07-23 2002-07-23 修飾したヒト胸腺ストローマ細胞リンホポエチン
JP2010153133A Pending JP2010279365A (ja) 2001-07-23 2010-07-05 修飾したヒト胸腺ストローマ細胞リンホポエチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010153133A Pending JP2010279365A (ja) 2001-07-23 2010-07-05 修飾したヒト胸腺ストローマ細胞リンホポエチン

Country Status (11)

Country Link
US (9) US7288633B2 (enExample)
EP (1) EP1417231B1 (enExample)
JP (2) JP5329016B2 (enExample)
AU (1) AU2002359238B2 (enExample)
CA (1) CA2454578C (enExample)
DK (1) DK1417231T3 (enExample)
ES (1) ES2422879T3 (enExample)
MX (1) MXPA04000631A (enExample)
PL (1) PL371773A1 (enExample)
PT (1) PT1417231E (enExample)
WO (1) WO2003032898A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371773A1 (en) * 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
ATE555194T1 (de) * 2001-12-18 2012-05-15 Cancer Rec Tech Ltd Methode zur herstellung von proliferierenden und differenzierenden zelllinien
SI1651247T1 (sl) * 2003-07-18 2009-02-28 Schering Corp Zdravljenje in diagnoza neoplazem z uporabo timusnega stromalnega limfopoietina
US20050249712A1 (en) 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
SE532251C2 (sv) * 2006-11-28 2009-11-24 Theravac Pharmaceuticals Ab Nya formuleringar av TSLP för behandling av TH2-medierade inflammatoriska sjukdomar genom vaccinering
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
WO2009032954A1 (en) * 2007-09-04 2009-03-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2213682A1 (en) 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
GB0918782D0 (en) * 2009-10-26 2009-12-09 St Georges Hosp Medical School A protein as an adjuvant for a vaccine
ES2784123T3 (es) 2009-11-04 2020-09-22 Merck Sharp & Dohme Anticuerpo anti TSLP genomodificado
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
HRP20210650T1 (hr) 2015-09-09 2021-05-28 Novartis Ag Protutijela koja vežu timusni stromalni limfopoetin (tslp) i postupci uporabe protutijela
US11001624B2 (en) 2016-04-05 2021-05-11 Vib Vzw TSLP inhibitors
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011912A (en) * 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
ATE188610T1 (de) 1992-04-30 2000-01-15 Amgen Inc Methoden zur behandlung von interleukin- 1 und - tumor - nekrose - faktor - verursachten krankheiten
GB9209874D0 (en) 1992-05-07 1992-06-24 Ml Lab Plc Pharmaceutical compositions
WO1995000103A2 (en) 1993-06-15 1995-01-05 Il-Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
JP2002526079A (ja) 1998-09-21 2002-08-20 シェーリング コーポレイション ヒトインターロイキン−ｂ５０、治療的使用
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
DE69936105T3 (de) 1998-11-13 2017-07-27 Immunex Corporation Menschliche tslp nukleinsäuren und polypeptide
EP1140976A4 (en) 1998-12-30 2003-05-21 Millennium Pharm Inc SECRETED PROTEINS AND THEIR USES
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
EP1712239A3 (en) 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
ES2391124T3 (es) 2000-06-28 2012-11-21 Amgen Inc. Moléculas de receptor de linfopoyetina estromal tímica y usos de las mismas
US6955895B2 (en) 2000-06-28 2005-10-18 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
PL371773A1 (en) 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
GB2381685A (en) 2001-10-30 2003-05-07 Amino Holdings Ltd Gateway device for converting digital signals to analogue signals
AU2003208888B2 (en) * 2002-02-01 2006-10-19 Merck Sharp & Dohme Llc Uses of mammalian cytokine; related reagents
HRP20020453A2 (en) 2002-05-23 2003-12-31 Pliva D D 1,3-diaza-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
SI1651247T1 (sl) 2003-07-18 2009-02-28 Schering Corp Zdravljenje in diagnoza neoplazem z uporabo timusnega stromalnega limfopoietina
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
EP1793856A2 (en) 2004-08-20 2007-06-13 Amgen Inc. Methods and compositions for treating allergic inflammation
CA2635599C (en) 2006-01-13 2014-06-17 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
JP5059119B2 (ja) 2006-12-14 2012-10-24 シェーリング コーポレイション 操作された抗ｔｓｌｐ抗体
CN102027012A (zh) 2007-06-20 2011-04-20 Irm责任有限公司 用于治疗变应性疾病的方法和组合物

Also Published As

Publication number Publication date
US20100167393A1 (en) 2010-07-01
PT1417231E (pt) 2013-07-29
US20140093956A1 (en) 2014-04-03
US20210102955A1 (en) 2021-04-08
US8598318B2 (en) 2013-12-03
US9045558B2 (en) 2015-06-02
US7288633B2 (en) 2007-10-30
US7709217B2 (en) 2010-05-04
ES2422879T3 (es) 2013-09-16
EP1417231A2 (en) 2004-05-12
MXPA04000631A (es) 2004-06-25
US20070218523A1 (en) 2007-09-20
US20160377630A1 (en) 2016-12-29
US20110230637A1 (en) 2011-09-22
CA2454578A1 (en) 2003-04-24
US20150252089A1 (en) 2015-09-10
JP2010279365A (ja) 2010-12-16
AU2002359238B2 (en) 2008-01-17
EP1417231B1 (en) 2013-06-19
CA2454578C (en) 2013-06-25
DK1417231T3 (da) 2013-07-22
PL371773A1 (en) 2005-06-27
WO2003032898A3 (en) 2003-08-14
JP2005505293A (ja) 2005-02-24
US20130023647A1 (en) 2013-01-24
US20080145866A1 (en) 2008-06-19
EP1417231A4 (en) 2004-12-15
US7973151B2 (en) 2011-07-05
WO2003032898A2 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
US9045558B2 (en) Nucleic acids encoding modified human thymic stromal lymphopoietin
JP5918817B2 (ja) 生物におけるイムノモデュレーションのための組成物および方法
CA2327349C (en) Il-2 selective agonists and antagonists
US5552303A (en) DNA encoding epithelium-derived T-cell factor
JP4426724B2 (ja) Ｌｄｃａｍと称される分子
PT772624E (pt) Interleucina-15
SK287039B6 (sk) Chimerický glykozylovaný proteín - sIL-6R/IL-6 a jeho analógy, DNA sekvencia, transformované cicavčie bunky obsahujúce DNA vektor, spôsob výroby chimerického proteínu, farmaceutický prostriedok s jeho obsahom a jeho použitie
KR100439290B1 (ko) 인터로이칸-18을인식하는신규의폴리펩티드
EP1451333B1 (en) Ul16 binding protein 4
AU2002359238A1 (en) Modified human thymic stromal lymphopoietin
JP2011520959A (ja) 新規可溶性ｃｄ８３ポリペプチド、配合物および使用法
FI117054B (fi) Interleukiini-15:n valmistusmenetelmä ja sitä koodaava DNA-sekvenssi
US20050118683A1 (en) Method for producing a polypeptide
JP3689111B2 (ja) インターロイキン１５
WO2001092301A2 (en) Placc, a novel human c-c chemokine isolated from placenta
WO2001000664A2 (en) Secreted alpha-helical protein-36
JP2007236387A (ja) 精製タンパク質の製造方法
JP2007238606A (ja) 精製タンパク質の製造方法
JP2007238605A (ja) 精製タンパク質の製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080416

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100802

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100823

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20101112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120601

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130531

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130724

R150 Certificate of patent or registration of utility model

Ref document number: 5329016

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term